Clinical Trial Update: Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating GSK3528869A, an HBV vaccine, in adults with chronic hepatitis B was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• GSK3528869A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B, Chronic | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-02-20